Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer

Ovarian cancer is one of the most common reproductive system tumors. The incidence of ovarian cancer in China is on the rise. Poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) is a DNA repair enzyme associated with DNA damage repair. PARPi takes PARP as a target to kill tumor cells, especially fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Ruihong, Ding, Ting, Li, Zhengyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326311/
https://www.ncbi.nlm.nih.gov/pubmed/37426808
http://dx.doi.org/10.3389/fphar.2023.1164395
_version_ 1785069398122299392
author Dong, Ruihong
Ding, Ting
Li, Zhengyu
author_facet Dong, Ruihong
Ding, Ting
Li, Zhengyu
author_sort Dong, Ruihong
collection PubMed
description Ovarian cancer is one of the most common reproductive system tumors. The incidence of ovarian cancer in China is on the rise. Poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) is a DNA repair enzyme associated with DNA damage repair. PARPi takes PARP as a target to kill tumor cells, especially for tumors with homologous recombination (HR) dysfunction. Currently, PARPi has been widely used in clinical practice, mainly for the maintenance of advanced ovarian epithelial cancer. The intrinsic or acquired drug resistance of PARPi has gradually become an important clinical problem with the wide application of PARPi. This review summarizes the mechanisms of PARPi resistance and the current progress on PARPi-based combination strategies.
format Online
Article
Text
id pubmed-10326311
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103263112023-07-08 Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer Dong, Ruihong Ding, Ting Li, Zhengyu Front Pharmacol Pharmacology Ovarian cancer is one of the most common reproductive system tumors. The incidence of ovarian cancer in China is on the rise. Poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) is a DNA repair enzyme associated with DNA damage repair. PARPi takes PARP as a target to kill tumor cells, especially for tumors with homologous recombination (HR) dysfunction. Currently, PARPi has been widely used in clinical practice, mainly for the maintenance of advanced ovarian epithelial cancer. The intrinsic or acquired drug resistance of PARPi has gradually become an important clinical problem with the wide application of PARPi. This review summarizes the mechanisms of PARPi resistance and the current progress on PARPi-based combination strategies. Frontiers Media S.A. 2023-06-23 /pmc/articles/PMC10326311/ /pubmed/37426808 http://dx.doi.org/10.3389/fphar.2023.1164395 Text en Copyright © 2023 Dong, Ding and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Dong, Ruihong
Ding, Ting
Li, Zhengyu
Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer
title Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer
title_full Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer
title_fullStr Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer
title_full_unstemmed Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer
title_short Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer
title_sort update on poly(adp-ribose) polymerase inhibitors resistance in ovarian cancer
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326311/
https://www.ncbi.nlm.nih.gov/pubmed/37426808
http://dx.doi.org/10.3389/fphar.2023.1164395
work_keys_str_mv AT dongruihong updateonpolyadpribosepolymeraseinhibitorsresistanceinovariancancer
AT dingting updateonpolyadpribosepolymeraseinhibitorsresistanceinovariancancer
AT lizhengyu updateonpolyadpribosepolymeraseinhibitorsresistanceinovariancancer

Ejemplares similares